Clinical Trial

Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This is a prospective, open label, single-arm study to evaluate the efficacy and safety of neoadjuvant pyrotinib in HER2+ breast cancer patients
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2020-02-27.
Status change: Not Yet Recruiting → Active, Not Recruiting 2026-01-05
Trial Details
NCT Number NCT04290793
Lead Sponsor Hebei Medical University Fourth Hospital
Conditions Breast Cancer
Enrollment 113 participants
Start Date 2020-03-01
Primary Completion 2026-12-01 (estimated)
Study Completion 2026-12-10 (estimated)
Updated on ClinicalTrials.gov 2026-01-07